Sigyn Therapeutics Files S-1/A Amendment

Ticker: SIGY · Form: S-1/A · Filed: Apr 10, 2024 · CIK: 1642159

Sigyn Therapeutics, Inc. S-1/A Filing Summary
FieldDetail
CompanySigyn Therapeutics, Inc. (SIGY)
Form TypeS-1/A
Filed DateApr 10, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$12.80, $14.08, $5.50, $0.0001, $0.01
Sentimentneutral

Sentiment: neutral

Topics: Sigyn Therapeutics, S-1/A, SEC Filing, Amendment, Beverly Hills

TL;DR

<b>Sigyn Therapeutics, Inc. has filed an S-1/A amendment, providing updated corporate and financial information.</b>

AI Summary

Sigyn Therapeutics, Inc. (SIGY) filed a Amended IPO Registration (S-1/A) with the SEC on April 10, 2024. Sigyn Therapeutics, Inc. filed an S-1/A amendment on April 10, 2024. The company's principal business address is 9190 W Olympic Blvd #263, Beverly Hills, CA 90212. The company was formerly known as Reign Resources Corp and Reign Sapphire Corp. The filing includes financial data for the fiscal years ending December 31, 2021, 2022, and 2023. Key dates mentioned include October 19, 2020, related to a Share Exchange Agreement.

Why It Matters

For investors and stakeholders tracking Sigyn Therapeutics, Inc., this filing contains several important signals. This amendment updates the company's registration statement, which is crucial for potential investors to assess its financial health and business prospects. The filing provides historical financial data and details on corporate structure changes, offering insights into the company's evolution and current standing.

Risk Assessment

Risk Level: low — Sigyn Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a previous registration statement, indicating ongoing regulatory processes rather than new material events.

Analyst Insight

Investors should review the S-1/A filing for the latest financial disclosures and corporate updates from Sigyn Therapeutics.

Key Numbers

  • 2024-04-10 — Filing Date (S-1/A filing date)
  • 1231 — Fiscal Year End (Company's fiscal year end)
  • 2021-12-31 — Fiscal Year End (Financial data period)
  • 2022-12-31 — Fiscal Year End (Financial data period)
  • 2023-12-31 — Fiscal Year End (Financial data period)
  • 2020-05-12 — Date of Name Change (Former company name change)
  • 2020-10-19 — Share Exchange Agreement Date (Key corporate event date)

Key Players & Entities

  • Sigyn Therapeutics, Inc. (company) — Filer name
  • 9190 W Olympic Blvd #263 (location) — Business address
  • Beverly Hills (location) — Business address city
  • CA (location) — Business address state
  • Reign Resources Corp (company) — Former company name
  • Reign Sapphire Corp (company) — Former company name
  • 2024-04-10 (date) — Filing date
  • October 19, 2020 (date) — Share Exchange Agreement date

FAQ

When did Sigyn Therapeutics, Inc. file this S-1/A?

Sigyn Therapeutics, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on April 10, 2024.

What is a S-1/A filing?

A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Sigyn Therapeutics, Inc. (SIGY).

Where can I read the original S-1/A filing from Sigyn Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Sigyn Therapeutics, Inc..

What are the key takeaways from Sigyn Therapeutics, Inc.'s S-1/A?

Sigyn Therapeutics, Inc. filed this S-1/A on April 10, 2024. Key takeaways: Sigyn Therapeutics, Inc. filed an S-1/A amendment on April 10, 2024.. The company's principal business address is 9190 W Olympic Blvd #263, Beverly Hills, CA 90212.. The company was formerly known as Reign Resources Corp and Reign Sapphire Corp..

Is Sigyn Therapeutics, Inc. a risky investment based on this filing?

Based on this S-1/A, Sigyn Therapeutics, Inc. presents a relatively low-risk profile. The filing is an amendment to a previous registration statement, indicating ongoing regulatory processes rather than new material events.

What should investors do after reading Sigyn Therapeutics, Inc.'s S-1/A?

Investors should review the S-1/A filing for the latest financial disclosures and corporate updates from Sigyn Therapeutics. The overall sentiment from this filing is neutral.

How does Sigyn Therapeutics, Inc. compare to its industry peers?

Sigyn Therapeutics operates in the surgical and medical instruments and apparatus industry.

Are there regulatory concerns for Sigyn Therapeutics, Inc.?

The S-1/A filing is an amendment to a registration statement under the Securities Act of 1933, indicating ongoing compliance and disclosure requirements.

Industry Context

Sigyn Therapeutics operates in the surgical and medical instruments and apparatus industry.

Regulatory Implications

The S-1/A filing is an amendment to a registration statement under the Securities Act of 1933, indicating ongoing compliance and disclosure requirements.

What Investors Should Do

  1. Review the full S-1/A filing for detailed financial statements and business descriptions.
  2. Analyze the historical financial data for trends and performance indicators.
  3. Investigate the details of the Share Exchange Agreement and prior name changes.

Key Dates

  • 2024-04-10: S-1/A Filing — Amendment to registration statement
  • 2020-10-19: Share Exchange Agreement — Key corporate transaction date
  • 2020-05-12: Name Change — Transition from Reign Sapphire Corp

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates and revisions to the initial registration statement.

Filing Stats: 4,682 words · 19 min read · ~16 pages · Grade level 13.5 · Accepted 2024-04-10 17:28:58

Key Financial Figures

  • $12.80 — ctus based on an assumed offer price of $12.80 for each share of common stock. Each Se
  • $14.08 — Warrant will have an exercise price of $14.08 (assumed) per share, will be exercisabl
  • $5.50 — ed sales price for our common stock was $5.50 per share. The actual public offering p
  • $0.0001 — common stock in this offering less the $0.0001 per share exercise price of each such p
  • $0.01 — c offering price per Class A Unit minus $0.01 per share, and (ii) minus $0.01 per Ser
  • $7,195,576 — 2022, we have an accumulated deficit of $7,195,576 and a working capital deficit of $1,978
  • $1,978,396 — 95,576 and a working capital deficit of $1,978,396. As of December 31, 2023, we have an ac
  • $11,341,512 — 2023, we have an accumulated deficit of $11,341,512 and a working capital deficit of $3,489
  • $3,489,941 — 41,512 and a working capital deficit of $3,489,941. We plan to apply to have our shares
  • $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
  • $9 million — mate that we will receive approximately $9 million in gross proceeds from this offering (b

Filing Documents

Risk Factors

Risk Factors 6 Cautionary Note Regarding Forward-Looking-Statements 18

Use of Proceeds

Use of Proceeds 20 Determination of Offering Price 21 Market for our Common Stock and Related Stockholder Matters 2 1 Dividend Policy 21 Capitalization 22

Management's Discussion and Analysis of Financial Condition and Results of Operation

Management's Discussion and Analysis of Financial Condition and Results of Operation 24 Description of Business 38 Description of Property 48 Directors, Executive Officers, Promoters, and Control Persons 48

Executive Compensation

Executive Compensation 52

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 55

Underwriting

Underwriting 56 Certain Relationships and Related Transactions 61

Description of Securities

Description of Securities 65 Shares Eligible for Future Sales 68 Legal Matters 68 Experts 69 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 69 Where You Can Find More Information 69 Disclosure of Commission Position on Indemnification for Securities Act Liabilities 69

Financial Statements

Financial Statements F-1 You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus. PROSPECTUS SUMMARY Except as otherwise indicated, as used in this prospectus, references to the "Company," "we," "us," or "our" refer to Sigyn Therapeutics, Inc. The following summary highlights selected information contained in this prospectus, and it may not contain all of the information that is important to you. Before making an investment decision, you should read the entire prospectus carefully, including "Risk Factors" and our financial statements and related notes, included elsewhere in this prospectus. Our Company Sigyn Therapeutics, Inc. ("Sigyn", the "Company" "we," "us," or "our") is a development-stage company that creates blood purification technologies to overcome clearly defined limitations in healthcare. Sigyn Therapy, our lead product candidate, is being advanced to treat life-threatening conditions that are not addressed with market-cleared drug agents. Candidate treatment indications include endotoxemia, sepsis (a leading cause of hospital deaths), and drug-resistant viral and bacterial infections. We plan to initiate first-in-human feasibility studies of Sigyn Therapy TM in End-Stage Renal Disease (ESRD) patients with endotoxemia and concurrent inflammation, whose incidence is elevated among ~550,000 U.S. dialysis patients. To support the initiation of our proposed study, we have drafted an Investigational Device Exemption (IDE) for submission to the U.S. Food and Drug Administration ("FDA"). Our clinical study plan proposes to enroll 12-15 ESRD subjects to evaluate the safety of Sigyn Therapy at three clinical site location

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.